Vitamin K Antagonist Has a Higher Impact Than Heparin in Preventing Circuit Clotting in Chronic Haemodialysis Patients

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2020 Sep 9

PMID 32905339

Authors

Pierre-Yves Charles

Yannick Le Meur

Tugdual Tanquerel

Hubert Galinat

Affiliations

Soon will be listed here.

Abstract

Background: In dialysis sessions, some data suggest that decreasing or even avoiding additional anticoagulation by heparin is possible among patients already treated with oral anticoagulation. However, the required dose of heparin may actually depend on the pre-dialysis international normalized ratio (INR), which varies from one session to another. The aim of our study was to determine the respective role of INR and heparin dosing in the risk of circuit clotting during chronic haemodialysis.

Methods: From early 2012 to July 2016, we analysed the totality of dialysis sessions performed at Brest University Hospital among haemodialysis patients treated by vitamin K antagonists (VKA). We established a prediction of circuit clotting on the basis of a simplified score obtained by combining INR and heparin dosing.

Results: In total, 7184 dialysis sessions among chronic haemodialysis patients under VKA were identified, including 233 with clotting events. The mean INR without clotting events was 2.5 versus 1.8 with clotting events (P). Frequencies of circuit clotting were different according to INR group (INR <2.0, INR 2.0-3.0, INR >3.0; P). The protective role of VKA was higher than heparin, as shown by discriminant factor analysis (P. Our study established a predictive model of thrombosis risk of dialysis circuits in patients treated by VKA for a given heparin dose and a given INR. This model shows a marginal contribution of heparin to protect against the risk of thrombosis compared with VKA. Moreover, heparin would not appear to be necessary for patients with an INR >2.2.

References

Elliott M, Zimmerman D, Holden R . Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007; 50(3):433-40. DOI: 10.1053/j.ajkd.2007.06.017. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for.... Circulation. 2006; 114(7):e257-354. DOI: 10.1161/CIRCULATIONAHA.106.177292. View

Genovesi S, Rossi E, Gallieni M, Stella A, Badiali F, Conte F . Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2014; 30(3):491-8. DOI: 10.1093/ndt/gfu334. View

Boure T, Vanholder R . Which dialyser membrane to choose?. Nephrol Dial Transplant. 2004; 19(2):293-6. DOI: 10.1093/ndt/gfg508. View

Hoel R, Albright R, Beyer L, Santrach P, Magtibay D, Everson S . Correlation of point-of-care International Normalized Ratio to laboratory International Normalized Ratio in hemodialysis patients taking warfarin. Clin J Am Soc Nephrol. 2008; 4(1):99-104. PMC: 2615705. DOI: 10.2215/CJN.03360708. View

Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell R . Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77(12):1098-106. DOI: 10.1038/ki.2009.477. View

Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D . Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019; 34(6):923-933. DOI: 10.1093/ndt/gfz040. View

Coli L, Donati G, Cianciolo G, Raimondi C, Comai G, Panicali L . Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. J Vasc Access. 2006; 7(3):118-22. DOI: 10.1177/112972980600700305. View

Voskamp P, Rookmaaker M, Verhaar M, Dekker F, Ocak G . Vitamin K antagonist use and mortality in dialysis patients. Nephrol Dial Transplant. 2017; 33(1):170-176. DOI: 10.1093/ndt/gfx199. View

10.

Sood M, Komenda P, Sood A, Rigatto C, Bueti J . The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?. Chest. 2009; 136(4):1128-1133. DOI: 10.1378/chest.09-0730. View

11.

Pokorney S, Simon D, Thomas L, Fonarow G, Kowey P, Chang P . Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015; 170(1):141-8, 148.e1. DOI: 10.1016/j.ahj.2015.03.017. View

12.

Sohal A, Gangji A, Crowther M, Treleaven D . Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res. 2005; 118(3):417-22. DOI: 10.1016/j.thromres.2005.03.032. View

13.

Ocak G, Noordzij M, Rookmaaker M, Cases A, Couchoud C, Heaf J . Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J Thromb Haemost. 2018; 16(10):1953-1963. DOI: 10.1111/jth.14254. View

14.

De Vriese A, Caluwe R, Raggi P . The atrial fibrillation conundrum in dialysis patients. Am Heart J. 2016; 174:111-9. DOI: 10.1016/j.ahj.2016.01.010. View

15.

Krummel T, Scheidt E, Borni-Duval C, Bazin D, Lefebvre F, Nguyen P . Haemodialysis in patients treated with oral anticoagulant: should we heparinize?. Nephrol Dial Transplant. 2014; 29(4):906-13. DOI: 10.1093/ndt/gft522. View

16.

Szummer K, Carrero J . Warfarin therapy for atrial fibrillation in haemodialysis patients: mind the (evidence) gap. Nephrol Dial Transplant. 2015; 30(3):337-9. DOI: 10.1093/ndt/gfu412. View

17.

Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F . Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant. 2001; 16(5):987-93. DOI: 10.1093/ndt/16.5.987. View

18.

Boonyawat K, Wang L, Lazo-Langner A, Kovacs M, Yeo E, Schnurr T . The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thromb Haemost. 2016; 116(3):480-5. DOI: 10.1160/TH16-04-0320. View

19.

Holden R, Harman G, Wang M, Holland D, Day A . Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2007; 3(1):105-10. PMC: 2390984. DOI: 10.2215/CJN.01810407. View

20.

. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002; 17 Suppl 7:63-71. DOI: 10.1093/ndt/17.suppl_7.63. View